Erratum to: Polymorphisms of extrinsic death receptor apoptotic genes (FAS −670 G>A, FASL −844 T>C) in coronary artery disease

[1]  V. Prasad,et al.  Promoter polymorphism of FASL confers protection against female-specific cancers and those of FAS impact the cancers divergently , 2015, Tumor Biology.

[2]  J. Ernerudh,et al.  Soluble Fas ligand is associated with natural killer cell dynamics in coronary artery disease. , 2014, Atherosclerosis.

[3]  B. Saffari,et al.  Non-modifiable Factors of Coronary Artery Stenosis in Late Onset Patients with Coronary Artery Disease in Southern Iranian Population , 2014, Journal of cardiovascular and thoracic research.

[4]  Linfeng Zheng,et al.  FasL Gene -844T/C Mutation of Esophageal Cancer in South China and Its Clinical Significance , 2014, Scientific Reports.

[5]  Seung‐Jung Park,et al.  Association of Body Mass Index With Major Cardiovascular Events and With Mortality After Percutaneous Coronary Intervention , 2013, Circulation. Cardiovascular interventions.

[6]  N. Wong,et al.  Hypertension and cardiovascular disease: contributions of the framingham heart study. , 2013, Global heart.

[7]  A. Fazaeli,et al.  Functional Polymorphisms of FAS and FASL Gene and Risk of Breast Cancer – Pilot Study of 134 Cases , 2013, PloS one.

[8]  N. Agrawal,et al.  FAS-670 A/G and FAS-1377 G/A polymorphism in cell death pathway gene FAS and human male infertility , 2012 .

[9]  T. Akasaka,et al.  Diverse Roles of Macrophages in Atherosclerosis: From Inflammatory Biology to Biomarker Discovery , 2012, Mediators of inflammation.

[10]  S. Topal,et al.  The Relationship of Serum Soluble Fas Ligand (sFasL) Level with the Extent of Coronary Artery Disease , 2012, International Journal of Angiology.

[11]  Ya‐Wen Cheng,et al.  A Polymorphic −844T/C in FasL Promoter Predicts Survival and Relapse in Non–Small Cell Lung Cancer , 2011, Clinical Cancer Research.

[12]  B. Reichart,et al.  Genetic polymorphisms of TP53 and FAS promoter modulate the progression of coronary artery disease after coronary artery bypass grafting: a gender-specific view , 2011, Inflammation Research.

[13]  P. Kang,et al.  Apoptosis in Cardiovascular Diseases: Mechanism and Clinical Implications , 2010, Korean circulation journal.

[14]  M. Deljanin-Ilić,et al.  Serum Fas/FasL levels in dependence on clinical presentations of coronary disease and their relationship with risk factors. , 2010, Vojnosanitetski pregled.

[15]  Jalil Tavakkol-Afshari,et al.  Soluble Fas might serve as a diagnostic tool for gastric adenocarcinoma , 2010, BMC Cancer.

[16]  A. Dean,et al.  On Academics: OpenEpi: A Web-Based Epidemiologic and Statistical Calculator for Public Health , 2009 .

[17]  T. Ogihara,et al.  Fas promoter region gene polymorphism is associated with an increased risk for myocardial infarction , 2009, Hypertension Research.

[18]  Sebastian Will,et al.  RNAalifold: improved consensus structure prediction for RNA alignments , 2008, BMC Bioinformatics.

[19]  A. Langer,et al.  Increased Soluble Fas Plasma Levels in Subjects at High Cardiovascular Risk: Atorvastatin on Inflammatory Markers (AIM) Study, a Substudy of ACTFAST , 2007, Arteriosclerosis, thrombosis, and vascular biology.

[20]  X. Solé,et al.  SNPStats: a web tool for the analysis of association studies , 2006, Bioinform..

[21]  Todd Holden,et al.  A flexible computational framework for detecting, characterizing, and interpreting statistical patterns of epistasis in genetic studies of human disease susceptibility. , 2006, Journal of theoretical biology.

[22]  M. Bennett,et al.  Role of apoptosis in atherosclerosis and its therapeutic implications. , 2004, Clinical science.

[23]  A. Tortolani,et al.  Apoptosis: pathophysiology and therapeutic implications for the cardiac surgeon. , 2004, The Annals of thoracic surgery.

[24]  Ivo L. Hofacker,et al.  Vienna RNA secondary structure server , 2003, Nucleic Acids Res..

[25]  Jason H. Moore,et al.  Multifactor dimensionality reduction software for detecting gene-gene and gene-environment interactions , 2003, Bioinform..

[26]  G. Cooper,et al.  A Novel Polymorphic CAAT/Enhancer-Binding Protein β Element in the FasL Gene Promoter Alters Fas Ligand Expression: A Candidate Background Gene in African American Systemic Lupus Erythematosus Patients1 , 2003, The Journal of Immunology.

[27]  A. Bradbury,et al.  Apoptosis in vascular disease. , 2001, European journal of vascular and endovascular surgery : the official journal of the European Society for Vascular Surgery.

[28]  M. Tomonaga,et al.  Discrepant expression of membrane and soluble isoforms of Fas (CD95/APO‐1) in adult T‐cell leukaemia: soluble Fas isoform is an independent risk factor for prognosis , 1999, British journal of haematology.

[29]  R. Natarajan,et al.  Lipoxygenase products increase monocyte adhesion to human aortic endothelial cells. , 1999, Arteriosclerosis, thrombosis, and vascular biology.

[30]  P. Schuster,et al.  Complete suboptimal folding of RNA and the stability of secondary structures. , 1999, Biopolymers.

[31]  G. D. De Meyer,et al.  Cell composition, replication, and apoptosis in atherosclerotic plaques after 6 months of cholesterol withdrawal. , 1998, Circulation research.

[32]  J. Mountz,et al.  Differential expression of human Fas mRNA species upon peripheral blood mononuclear cell activation. , 1995, The Biochemical journal.

[33]  J. Nurnberger,et al.  A rapid non-enzymatic method for the preparation of HMW DNA from blood for RFLP studies. , 1991, Nucleic acids research.

[34]  R. Schwartz,et al.  Apoptosis. Basic concepts and implications in coronary artery disease. , 1999, Arteriosclerosis, thrombosis, and vascular biology.

[35]  Tom R. Gaunt,et al.  American Journal of Epidemiology Practice of Epidemiology Hardy-weinberg Equilibrium Testing of Biological Ascertainment for Mendelian Randomization Studies , 2022 .